Stellar Biotechnologies reported an increase in revenue Feb. 5, but operating expenses also rose, keeping its net losses steady at around $1.41 million for its fiscal first quarter. In the earnings release, the Port Hueneme manufacturer of proteins used in experimental therapies said it had $50,000 in revenue for the quarter ended Dec. 31, up…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
